Encorafenib,Cetuximab 
pfizer,eli lilly
[]
 so in this, arm c has to have access to enc, cetux as minimum on progression. the other study mentioned could have reasonably been a small single arm of combo just to make sure toxicity not horrendous.
Junior Doctor at Southampton. Tweets my own. No FCOI.